|

LM-108 antibody and sintilimab and chemotherapy Clinical Trials

1 actively recruiting trial

Also known as: Trial group 2

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Pulmonary Hospital, Shanghai, China1

Indications

  • PD-11
  • NSCLC1
  • Lung Cancer1
  • Cancer1

Other1 trial

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.